YD Bio LtdYDES
Price (close)
$4.77
Market cap
$337.7M
P/E
—
Revenue (FY)
$596,817
Net income
-$8.3M
Dividend yield
—
1-year total return
-66.5%
Net margin
-1392.6%
Revenue growth
16.9%
Debt / equity
—
What YD Bio Ltd does.
diagnostics, life science clinical services, and healthcare product commercialization. Our operations include DNA methylation-based oncology
testing programs in the United States conducted under a LDT framework in collaboration with CLIA-certified and CAP-accredited laboratory
partners. In addition to our diagnostics activities, we provide regulated life science distribution and clinical trial supply chain services
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | $350,131 | $510,360 | $596,817 |
| Net income | — | $13,560 | -$1.4M | -$8.3M |
| Free cash flow | — | -$55,947 | -$1.3M | -$8.0M |
More on YDES.
- YD Bio Ltd summary
- YD Bio Ltd financial statements
- YD Bio Ltd key metrics
- YD Bio Ltd health scores and style box
- YD Bio Ltd earnings
- YD Bio Ltd dividends
- YD Bio Ltd valuation
- YD Bio Ltd ownership and insiders
- YD Bio Ltd peers
Figures from YD Bio Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.